<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03803852</url>
  </required_header>
  <id_info>
    <org_study_id>1978/2018</org_study_id>
    <nct_id>NCT03803852</nct_id>
  </id_info>
  <brief_title>Rotation of Hydrophobic Acrylic Lenses - Rayner RA0800C &amp; Alcon Clareon &amp; Hoya Nanex</brief_title>
  <acronym>RayAXClaroNaro</acronym>
  <official_title>Rotation of Hydrophobic Acrylic Lenses - Rayner RA0800C &amp; Alcon Clareon &amp; Hoya Nanex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigational devices are approved intraocular lenses (IOL) intended to be implanted
      after phacoemulsification in individuals suffering from age-related cataract with the need of
      cataract surgery. Within the study, two different IOLs will be investigated and separately
      evaluated. Cataract surgery with IOL implantation will be performed in subjects who have
      signed an informed consent form. Postoperative examinations will be postoperative refraction,
      visual acuity, slitlamp examination, and rotation of the IOL within 1 hour, 1 week, 1 month
      and 4-7 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2019</start_date>
  <completion_date type="Anticipated">October 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 14, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study involves 3 different groups. One investigating the RayOne IOL and the other investigating the Clareon IOL. Those 2 groups will be evaluated separately.
Alcon Clareon group: 120 eyes Rayner RayOne group: 130 eyes Hoya Nanex group: 120 eyes</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of axial intraocular lens position</measure>
    <time_frame>7 months</time_frame>
    <description>Change in axis position of an intraocular lens Rayner RayOne or Alcon Clareon from end of surgery (baseline axis) to 1 hour, 1 week, 1 month and 4-7 months (end of study visit). The change in axis position will be evaluated with respect to the baseline measurement at the end of surgery. Differences in axis position will be described as rotation in degrees (0 to 360°)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decentration</measure>
    <time_frame>7 months</time_frame>
    <description>Decentration of the intraocular lens Rayner RayOne or Alcon Clareon will be measured with the Casia 2 OCT. Decentration will be described as &quot;Decentration in milimeter&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tilt</measure>
    <time_frame>7 months</time_frame>
    <description>Tilt of the intraocular lens Rayner RayOne or Alcon Clareon will be measured with the Casia 2 OCT. Tilt will be described as &quot;Tilt in degrees at a certain axis&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior chamber depth</measure>
    <time_frame>1 month</time_frame>
    <description>The anterior chamber depth (Axial position of the IOL) of the intraocular lens Rayner RayOne or Alcon Clareon will be measured with the Casia 2 OCT after 1 month. The anterior chamber depth will be measured in milimeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>7 months</time_frame>
    <description>BCVA will be measured at 1 week, 1 month and 4 to 7 months. The BCVA will be described as the minimum angle of resolution (logMar)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Age Related Cataracts</condition>
  <arm_group>
    <arm_group_label>0°</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 0°</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45°</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 45°</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90°</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 90°</description>
  </arm_group>
  <arm_group>
    <arm_group_label>135°</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 135°</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intraocular Lens Implantation</intervention_name>
    <description>Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex into the capsular bag using an injector, after removing of the human cristalline lens.</description>
    <arm_group_label>0°</arm_group_label>
    <arm_group_label>135°</arm_group_label>
    <arm_group_label>45°</arm_group_label>
    <arm_group_label>90°</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Uni- or bilateral age-related cataract necessitating phacoemulsification extraction
             and posterior IOL implantation

          -  Age: 45 to 95

          -  Need for spherical IOL correction between 10.00 and 30.00 D

          -  Preoperative pupil dilation in mydriasis ≥ 7.0 mm

        Exclusion Criteria:

          -  Preceding ocular surgery or trauma

               -  Recurrent intraocular inflammation of unknown etiology

               -  Uncontrolled glaucoma

               -  Uncontrolled systemic or ocular disease

               -  Blind fellow eye

               -  Microphthalmus

               -  Corneal abnormality (Corneal scaring)

               -  History of uveitis/iritis

               -  Iris neovascularization

               -  Proliferative diabetic retinopathy

               -  Pregnancy

               -  Lactation

               -  Females of childbearing age will be asked if pregnancy is possible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupert Menapace, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rupert Menapace, Prof.Dr.</last_name>
    <phone>0043-1-40400</phone>
    <phone_ext>- 66300</phone_ext>
    <email>rupert.menapace@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Schartmueller, Dr.</last_name>
    <phone>0043-1-40400</phone>
    <phone_ext>79450</phone_ext>
    <email>daniel.schartmueller@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna Allgemeines Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupert Menapace, Prof.</last_name>
      <phone>014040066300</phone>
      <email>rupert.menapace@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 7, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2019</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Rupert Menapace</investigator_full_name>
    <investigator_title>Ao.Univ.Prof.Dr. Rupert Menapace</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

